Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Background: Retrospective large patient database studies have reported conflicting findings regarding diabetes risks associated with antipsychotics. This study compared two study designs to assess antipsychotic-related diabetes risk.
Methods: Claims data were analyzed for over 60,000 patients with psychosis, both treated and untreated with antipsychotics, between January 1999 and April 2002. Diabetes odds ratios for patients treated with antipsychotics versus untreated patients were estimated. All patients and patients stratified by low, medium, and high antipsychotic dose were analyzed. Logistic regression controlled for age, sex, type of psychosis, length of observation/treatment, preexisting excess weight, and use of other drugs.
Results: Under a less rigorous study design, diabetes risk was statistically significant with all antipsychotics versus no treatment. Under a more rigorous design, relative odds for quetiapine and risperidone declined and became statistically nonsignificant, whereas those for olanzapine and conventional antipsychotics increased and remained significant. By dose, only quetiapine showed a lack of statistical significance at all dose levels.
Conclusions: In database studies estimated risks of antipsychotic-related diabetes are affected by study design. With a more rigorous design, the risk associated with quetiapine and risperidone was not significantly different from that in untreated patients. These findings may explain inconsistent findings in pharmacoepidemiologic database studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/10401230500464596 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!